screen_shot_2012-07-05_at_11

New chairman of the board for Dendreon

pharmafile | July 5, 2012 | Appointment | Business Services, Manufacturing and Production, Research and Development, Sales and Marketing |  Dendreon, Provenge, johnson, prostate cancer 

Dendreon has announced that its president and chief executive John Johnson has assumed the additional title of chairman of the board.

Johnson succeeds Dr Mitchell Gold as chairman. Gold will continue to serve as a director and the changes are part of a succession plan the firm previously announced in February this year.

Douglas Watson, lead independent director of the company’s board, said: “John has proven to be an outstanding leader, and is making important progress in positioning Dendreon for long-term success. As chairman, he will set the vision for Dendreon as we work to provide Provenge to patients around the world.”

Advertisement

Johnson commented: “This is an exciting time in the prostate cancer space, and Dendreon has a unique position in the marketplace with an entirely new treatment paradigm. I look forward to working with the board and Dendreon management team as we work to improve our top and bottom line performance, creating value for shareholders and patients alike.”

Related Content

Blue Earth announces first UK patient received prostate cancer injection

Blue Earth Therapeutics, a clinical-stage company specialising in targeted radiotherapeutics, has announced that the first …

Johnson & Johnson seeks EMA approval to accelerate prostate cancer treatment

Johnson & Johnson has submitted an application to the European Medicines Agency for an indication …

Biocon Biologics gains EU approval for bone health therapies

Biocon Biologics has announced that the European Commission has granted marketing authorisation for its denosumab …

The Gateway to Local Adoption Series

Latest content